Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business HighlightsUnusual WhalesAug 3, 2026 at 06:03 AMOcular is set to submit the NDA for AXPAXLI TM, targeting wet AMD, in Q4 2026 after a successful Type C Meeting with the U.S. FDA in May 2026.
